Financing ·
TransCode Therapeutics, Inc. filed an Amended and Restated Certificate of Designation of Preferences, Rights and…
RNAZTranscode Therapeutics, Inc.
TransCode Therapeutics, Inc. filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock on July 16, 2026. Following approval from the Board of Directors and a majority of Series C Preferred Stock holders, the amendment increased the beneficial ownership limitation for Series C holders from 4.99% to 9.99%. The filing also included non-substantive corrections to scrivener's errors, with no additional securities issued or sold. TransCode Therapeutics, Inc. is a biotechnology company focused on RNA therapeutics.